# CVS HEALTH Corp: Form 10-Q for the period ended Jun 30, 2012

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2012-08-07
- Accepted by EDGAR: Aug 7, 2012, 16:44 ET
- Period: 2012-06-30
- Accession: 0001104659-12-055261
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000110465912055261/a12-13824_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000110465912055261/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-04-01 to 2012-06-30 | $30.71bn | us-gaap:Revenues |
| Revenue | 6 months, 2012-01-01 to 2012-06-30 | $61.51bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2012-04-01 to 2012-06-30 | $25.27bn | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2012-01-01 to 2012-06-30 | $50.95bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2012-04-01 to 2012-06-30 | $5.45bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2012-01-01 to 2012-06-30 | $10.56bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2012-04-01 to 2012-06-30 | $1.71bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2012-01-01 to 2012-06-30 | $3.11bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-04-01 to 2012-06-30 | $132.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2012-01-01 to 2012-06-30 | $264.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-04-01 to 2012-06-30 | $610.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2012-01-01 to 2012-06-30 | $1.11bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-04-01 to 2012-06-30 | $965.0m | us-gaap:ProfitLoss |
| Net income | 6 months, 2012-01-01 to 2012-06-30 | $1.74bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2012-04-01 to 2012-06-30 | $0.75 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2012-01-01 to 2012-06-30 | $1.34 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-04-01 to 2012-06-30 | $0.76 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2012-01-01 to 2012-06-30 | $1.35 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-04-01 to 2012-06-30 | 1,287,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2012-01-01 to 2012-06-30 | 1,298,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2012-01-01 to 2012-06-30 | $4.02bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2012-01-01 to 2012-06-30 | $818.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2012-01-01 to 2012-06-30 | $420.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months, 2012-01-01 to 2012-06-30 | $2.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2012-06-30 | $1.82bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-06-30 | $19.30bn | us-gaap:AssetsCurrent |
| Total assets | at 2012-06-30 | $65.59bn | us-gaap:Assets |
| Current liabilities | at 2012-06-30 | $13.14bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2012-06-30 | $9.21bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2012-06-30 | $5.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2012-06-30 | $200.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2012-06-30 | $37.91bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Market risk

As filed, 283 characters.

As of June 30, 2012, the Company had no derivative financial instruments or derivative commodity instruments in place and believes its exposure to market risk associated with other financial instruments, principally interest rate risk inherent in its debt portfolio, is not material.

## Controls and procedures

As filed, 6,448 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of June 30, 2012, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended June 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part II Item 1

### Legal Proceedings

Certain legal proceedings in which we are involved are discussed in Part I, Item 3 of our 2011Annual Report on Form 10-K. The following discussion is limited to certain recent developments concerning our legal proceedings and should be read in conjunction with those earlier reports.

1\. Caremark was named in a putative class action lawsuit filed in October 2003 in Alabama state court by John Lauriello, purportedly on behalf of participants in the 1999 settlement of various securities class action and derivative lawsuits against Caremark and others. Other defendants include insurance companies that provided coverage to Caremark with respect to the settled lawsuits. The Lauriello lawsuit seeks approximately $3.2 billion in compensatory damages plus other non-specified damages based on allegations that the amount of insurance coverage available for the settled lawsuits was misrepresented and suppressed. A similar lawsuit was filed in November 2003 by Frank McArthur, also in Alabama state court, naming as defendants, among other, Caremark and several insurance companies involved in the 1999 settlement. This lawsuit was stayed as a later-filed class action, but McArthur was subsequently allowed to intervene in the Lauriello action. A hearing was held in May 2012 on class certification and adequacy issues, but the court has not yet issued a ruling on these matters.

2\. In August 2009, the Company was notified by the U.S. Federal Trade Commission (“FTC”) that it was conducting a non-public investigation into certain of the Company’s business practices. In March 2010, the Company learned that various State Attorneys General offices and certain other government agencies were conducting a multi-state investigation of the Company regarding issues similar to those being investigated by the FTC. At this time, 28 states, the District of Columbia, and the County of Los Angeles, are known to be participating in this multi-state investigation. In May 2012, a proposed consent order previously entered into between the FTC and the Company became final, and all aspects of the FTC investigation are now officially concluded. The final consent order prohibits the Company from misrepresenting the price or cost of Medicare Part D prescription drugs, or other prices of costs associated with Medicare Part D prescription drug plans. In addition, the Company paid $5 million in consumer redress, to be distributed to impacted RxAmerica Medicare Part D beneficiaries. The final order contains no allegations of antitrust law violations or anti-competitive behavior related to the Company’s business practices or its products or service offerings. With respect to the multi-state investigation, the Company continues to cooperate in this investigation.

3\. In November 2009, a securities class action lawsuit was filed in the United States District Court for the District of Rhode Island purportedly on behalf of purchasers of CVS Caremark Corporation stock between May 5, 2009 and November 4, 2009. The lawsuit names the Company and certain officers as defendants and includes allegations of securities fraud relating to public disclosures made by the Company concerning the PBM business and allegations of insider trading. In addition, a shareholder derivative lawsuit was filed in December 2009 in the same court against the directors and certain officers of the Company. A derivative lawsuit is a lawsuit filed by a shareholder purporting to assert claims on behalf of a corporation against directors and officers of the corporation. This lawsuit, which was stayed pending developments in the related securities class action, includes allegations of, among other things, securities fraud, insider trading and breach of fiduciary duties and further alleges that the Company was damaged by the purchase of stock at allegedly inflated prices under its share repurchase program. In January 2011, both lawsuits were transferred to the United States District Court for the District of New Hampshire. In June 2012, the court granted the Company’s motion to dismiss the securities class action. The plaintiffs subsequently filed a notice of appeal of the court’s ruling on the motion to dismiss. The derivative lawsuit will remain stayed pending the outcome of this appeal of the securities class action.

### Part II Item 2

### Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended June 30, 2012, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2011 Repurchase Program.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| April 1, 2012 through April 30, 2012 | 10,478,625 | $ 44.10 | 10,478,625 | $ 1,726,592,805 |
| May 1, 2012 through May 31, 2012 | 9,250,000 | $ 45.16 | 9,250,000 | $ 1,308,858,655 |
| June 1, 2012 through June 30, 2012 | 6,889,500 | $ 44.79 | 6,889,500 | $ 1,000,290,643 |
| Totals | 26,618,125 | $ 44.65 | 26,618,125 |  |

32

### Part II Item 6

### Exhibits

Filed Aug 7, 2012.
Source: SEC EDGAR, the filing index for accession 0001104659-12-055261. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
